COPENHAGEN/LONDON, March 25 (Reuters) - GlaxoSmithKline (GSK.L) and Genmab (GEN.CO) said on Thursday that two rival drugmakers had filed a patent infringement related complaint with a Californian district court over leukaemia drug Arzerra.
U.S.-based Biogen Idec Inc (BIIB.O) and Swiss Roche (ROG.VX) filed the complaint "based on GSK's manufacture, marketing and sale of Arzerra in the U.S. for the treatment of fludarabine and alemtuzumab...
Ofatumumab Demonstrates High Activity in Newly Diagnosed Patients With CLL: Presented at ICHM
Doctor's Guide
DGDispatch
By Dru S. Dace, PhD
WHISTLER, British Columbia -- March 24, 2010 -- In a report presented here on March 21 at the 14th Annual International Congress on Hematologic Malignancies (ICHM), a novel anti-CD20 antibody, ofatumumab, demonstrated high activity in patients with previously untreated chronic lymphocytic leukaemia (CLL).
...
UPDATE 1-Genzyme says combo approach aids leukemia patients
Mon Dec 7, 2009 4:40pm EST
* Campath-Fludara combo slows progression of leukemia
* Genzyme to seek expanded label indication based on data
CHICAGO, Dec 7 (Reuters) - Genzyme Corp (GENZ.O) on Monday said patients taking its leukemia drug Campath in combination with Fludara in a clinical trial saw less disease progression than patients taking Fludara alone.
Researchers from the UK have reported a 48% progression-free survival in patients with relapsed diffuse large B-cell lymphoma (DLBCL) following reduced-intensity allogeneic stem cell transplantation. The details of this Phase II study appeared in the January 20, 2009 issue of the Journal of Clinical Oncology.[1]
Reduced-intensity allogeneic stem cell transplants for patients with relapsed low- and high-grade lymphoma has been effective, potentially curative therapy. A previous study...
Combination alemtuzumab and rituximab may be an effective early treatment for patients with high-risk chronic lymphocytic leukemia, according to data from a phase-2 trial.
Researchers examined the safety and efficacy of alemtuzumab (Campath, Ilex Pharmaceuticals) and rituximab (Rituxan, Genentech) for the early treatment of high-risk CLL in 30 patients who were previously untreated and had at least one marker for high-risk disease.
